Taro Pharmaceuticals Inc

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: -

Employees: -

Market Cap: $1.6B

Website

Clinical Trials

A Study Comparing Tazarotene Cream 0.1% to Tazorac® and Both to a Placebo Control in the Treatment of Acne Vulgaris

Phase 1

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Tazarotene Cream 0.1%
Drug: Tazorac®
Drug: Placebo

First Posted Date: 2015-04-08

Last Posted Date: 2017-05-04

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 1077

Registration Number: NCT02411955

Safety and Efficacy of NVXT Solution in Mild-to-Moderate Fungal Infection of the Toe Nail

Phase 2

Completed

Conditions: Onychomycosis

Interventions: Drug: NVXT Solution
Drug: Vehicle of test product

First Posted Date: 2015-01-22

Last Posted Date: 2018-09-19

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 47

Registration Number: NCT02343627

Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis

Phase 4

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Topicort® (desoximetasone) Topical Spray, 0.25%

First Posted Date: 2015-01-16

Last Posted Date: 2023-03-28

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 129

Registration Number: NCT02340169

Locations: 🇺🇸
Taro Pharmaceuticals USA Inc., Hawthorne, New York, United States

Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis

Phase 1

Completed

Conditions: Tinea Pedis

Interventions: Drug: Naftin® Gel 2%
Drug: Placebo Topical Gel
Drug: Naftifine Hydrochloride Gel 2%

First Posted Date: 2015-01-09

Last Posted Date: 2018-09-06

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 1519

Registration Number: NCT02335255

Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tinea Pedis

Phase 1

Completed

Conditions: Tinea Pedis

Interventions: Drug: Placebo Topical Cream
Drug: Naftin® (Naftifine Hydrochloride) Cream 2%
Drug: Naftifine Hydrochloride Cream 2%

First Posted Date: 2014-05-07

Last Posted Date: 2017-05-09

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 890

Registration Number: NCT02132260

A Study to Evaluate the Safety and Bioequivalence of Mupirocin Calcium Cream, 2% and Bactroban® Cream and Compare Both to a Vehicle in Treatment of Secondarily Infected Traumatic Skin Lesions.

Phase 1

Completed

Conditions: Secondarily Infected Traumatic Skin Lesions

Interventions: Drug: Bactroban® Cream
Drug: Cream vehicle of test product
Drug: Mupirocin Calcium Cream, 2%

First Posted Date: 2013-06-12

Last Posted Date: 2019-05-09

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 1902

Registration Number: NCT01876550

Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.

Phase 1

Completed

Conditions: Actinic Keratosis

Interventions: Drug: Imiquimod Topical Cream 3.75%
Drug: Vehicle Topical Cream
Drug: Zyclara® (imiquimod) Topical Cream 3.75%

First Posted Date: 2013-02-11

Last Posted Date: 2014-01-22

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 443

Registration Number: NCT01788007

A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris

Phase 1

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Duac® Topical Gel
Drug: Placebo Topical Gel
Drug: Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel

First Posted Date: 2013-01-17

Last Posted Date: 2014-01-22

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 650

Registration Number: NCT01769664

Study Comparing Clindamycin Phosphate and Benzoyl Peroxide Gel to Acanya® Gel and Both to a Vehicle Control in the Treatment of Acne Vulgaris

Phase 1

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%
Drug: Acanya® Gel, 1.2%/2.5%
Drug: Vehicle of test product

First Posted Date: 2013-01-16

Last Posted Date: 2017-05-05

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 1215

Registration Number: NCT01769235

A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis

Phase 1

Completed

Conditions: Actinic Keratosis

Interventions: Drug: Diclofenac Sodium Gel 3%
Drug: Vehicle Topical Gel
Drug: Solaraze® (diclofenac sodium) Gel 3%

First Posted Date: 2012-12-05

Last Posted Date: 2014-01-22

Lead Sponsor: Taro Pharmaceuticals USA

Target Recruit Count: 435

Registration Number: NCT01742663

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy